SYRE Q2 2024 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$44M

Net Income

-$39M

EPS (Diluted)

$-0.86

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$62M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$436M

Total Liabilities

$62M

Stockholders' Equity

$374M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$688,000	-100.0%
Gross Profit	$0	$688,000	-100.0%
Operating Income	-$44M	-$159M	+72.3%
Net Income	-$39M	-$217M	+82.1%